

Richard Barohn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10744410/publications.pdf>

Version: 2024-02-01

26
papers

1,162
citations

471509

17
h-index

552781

26
g-index

27
all docs

27
docs citations

27
times ranked

1588
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre-specified and post hoc analyses. <i>Muscle and Nerve</i> , 2022, 66, 39-49.	2.2	16
2	Clinical features of LRP4/ agrin antibody-positive myasthenia gravis: A multicenter study. <i>Muscle and Nerve</i> , 2020, 62, 333-343.	2.2	46
3	Practice advisory: Thymectomy for myasthenia gravis (practice parameter update). <i>Neurology</i> , 2020, 94, 705-709.	1.1	29
4	Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. <i>Lancet Neurology</i> , 2019, 18, 259-268.	10.2	139
5	Using Adaptive Designs to Avoid Selecting the Wrong Arms in Multiarm Comparative Effectiveness Trials. <i>Statistics in Biopharmaceutical Research</i> , 2019, 11, 375-386.	0.8	5
6	Learning from the past: reflections on recently completed myasthenia gravis trials. <i>Annals of the New York Academy of Sciences</i> , 2018, 1412, 5-13.	3.8	11
7	An instrumented timed up and go in facioscapulohumeral muscular dystrophy. <i>Muscle and Nerve</i> , 2018, 57, 503-506.	2.2	13
8	Longitudinal Screening Detects Cognitive Stability and Behavioral Deterioration in ALS Patients. <i>Behavioural Neurology</i> , 2018, 2018, 1-7.	2.1	19
9	Review process for IVIg treatment. <i>Neurology: Clinical Practice</i> , 2018, 8, 429-436.	1.6	9
10	A Phonetic Complexity-Based Approach for Intelligibility and Articulatory Precision Testing: A Preliminary Study on Talkers With Amyotrophic Lateral Sclerosis. <i>Journal of Speech, Language, and Hearing Research</i> , 2018, 61, 2205-2214.	1.6	15
11	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2017, 69, 898-910.	5.6	52
12	A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 144.	2.7	29
13	Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. <i>Muscle and Nerve</i> , 2016, 53, 165-168.	2.2	24
14	Frontiers: Integration of a Research Participant Registry with Medical Clinic Registration and Electronic Health Records. <i>Clinical and Translational Science</i> , 2015, 8, 405-411.	3.1	8
15	Building efficient comparative effectiveness trials through adaptive designs, utility functions, and accrual rate optimization: finding the sweet spot. <i>Statistics in Medicine</i> , 2015, 34, 1134-1149.	1.6	23
16	A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2015, 16, 345-352.	1.7	26
17	NP001 regulation of macrophage activation markers in ALS: A phase I clinical and biomarker study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2014, 15, 601-609.	1.7	49
18	North America and South America (NA-SA) neuropathy project. <i>International Journal of Neuroscience</i> , 2013, 123, 563-567.	1.6	24

#	ARTICLE	IF	CITATIONS
19	Idiopathic Inflammatory Myopathies. <i>Seminars in Neurology</i> , 2012, 32, 227-236.	1.4	37
20	Inclusion Body Myositis. <i>Seminars in Neurology</i> , 2012, 32, 237-245.	1.4	43
21	Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. <i>Molecular Genetics and Metabolism</i> , 2012, 107, 456-461.	1.1	93
22	Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (CHAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle T. <i>Arthritis Care and Research</i> , 2011, 63, S118-57.	3.4	288
23	Distal Myopathies. <i>Seminars in Neurology</i> , 1999, 19, 45-58.	1.4	6
24	Approach to Peripheral Neuropathy and Neuronopathy. <i>Seminars in Neurology</i> , 1998, 18, 7-18.	1.4	98
25	Cryptogenic Sensory and Sensorimotor Polyneuropathies. <i>Seminars in Neurology</i> , 1998, 18, 105-111.	1.4	41
26	Distal Myopathies and Dystrophies. <i>Seminars in Neurology</i> , 1993, 13, 247-255.	1.4	19